看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。2 H8 ^ [. E1 h& l) J" A
, V% s9 b E: @ R$ ] Z7 c. T! F3 Z( \" _ F5 A
Currently available feasibility data for possible combination strategies. : L) E N+ o3 E. ^( E) z4 |4 `+ t
————————————————————————————————$ B; @, t, c3 ]
Combination Feasibility according to preliminary data
5 q4 E7 \6 V) Q0 c& M9 }2 P——————————————————————————————————# T& F; ?* J$ X* P+ V
Bevacizumab + sorafenib Yes, reduced dose 7 v" B. t+ M- q3 G# {- Z
Bevacizumab + sunitinib† No + P9 p; A1 a0 @8 _+ I: W. E9 f
Bevacizumab + temsirolimus Yes
3 J5 V$ r8 n) h' G' d( z* b1 UBevacizumab + everolimus Yes # f7 a# r' y7 [
Sorafenib + sunitinib ?
8 H: d: ]2 J5 K; w/ q# xSorafenib + temsirolimus Yes, reduced dose / B/ k0 W1 i) A
Sorafenib + everolimus Yes, reduced dose 3 w2 g0 c: t0 T3 v6 G) N1 B
Sunitinib + temsirolimus† No
1 B* w( H6 w( eSunitinib + everolimus ? 9 P8 F) b" x5 t; ^3 g- A8 F
Temsirolimus + everolimus ?
* s* M6 R+ v o% s6 |8 E% |————————————————————4 j+ j& p) C8 Z3 R3 L
†Led to US FDA warning.7 } K4 l5 R- e; Y
?: As yet unattempted combination./ U5 ~2 ]/ @" E" p# o9 R6 t
|
显身卡
